The mission of the Pilot and Feasibility Program (P&F) of the Penn DRC is foster the development of new investigators and to provide seed-support for innovative high-risk diabetes-related projects, with an increasing emphasis on clinical and translational science. Over the past 2 funding periods (10 years), the Pilot and Feasibility Program has been highly successful in this regard. 39 investigators received P&F Awards and, of these, 34 (87%) have garnered NIH support, the majority as R01s directly related to their Pilot Awards. During the previous funding period 30 grants were awarded from among 115 applications submitted by investigators representing 22 Departments spanning multiple Schools and Institutes on the campus of the University of Pennsylvania and other Philadelphia institutions. Of the funded grants, nearly 80% were to new investigators and more than 25% were dedicated to clinical and translational projects. During the next funding period we propose to continue the core mission of the Pilot and Feasibility Program. Given the past successes of the program, the increased cost of performing research in the setting of a more competitive general funding environment, and the clear need based on the escalating numbers of applications from new and established investigators both within and outside of the diabetes research community, we feel that this program continues to be well justified. We also propose to administer one additional Pilot and Feasibility Award dedicated to the use of the exciting new Regional Metabolomics Core at Princeton University that is proposed in this application and consistent with the P&F mission.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
5P30DK019525-37
Application #
8469484
Study Section
Special Emphasis Panel (ZDK1-GRB-S)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
37
Fiscal Year
2013
Total Cost
$342,228
Indirect Cost
$110,865
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Wangensteen, Kirk J; Wang, Yue J; Dou, Zhixun et al. (2018) Combinatorial genetics in liver repopulation and carcinogenesis with a in vivo CRISPR activation platform. Hepatology 68:663-676
Brown, Justin C; Damjanov, Nevena; Courneya, Kerry S et al. (2018) A randomized dose-response trial of aerobic exercise and health-related quality of life in colon cancer survivors. Psychooncology 27:1221-1228
Wooldridge, Amy L; Bischof, Robert J; Liu, Hong et al. (2018) Late-gestation maternal dietary methyl donor and cofactor supplementation in sheep partially reverses protection against allergic sensitization by IUGR. Am J Physiol Regul Integr Comp Physiol 314:R22-R33
Kim, Boa; Jang, Cholsoon; Dharaneeswaran, Harita et al. (2018) Endothelial pyruvate kinase M2 maintains vascular integrity. J Clin Invest 128:4543-4556
Gibson, Christopher E; Boodhansingh, Kara E; Li, Changhong et al. (2018) Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency. Horm Res Paediatr 89:413-422
Hill, David A; Lim, Hee-Woong; Kim, Yong Hoon et al. (2018) Distinct macrophage populations direct inflammatory versus physiological changes in adipose tissue. Proc Natl Acad Sci U S A 115:E5096-E5105
Kim, Yong Hoon; Marhon, Sajid A; Zhang, Yuxiang et al. (2018) Rev-erb? dynamically modulates chromatin looping to control circadian gene transcription. Science 359:1274-1277
Mowel, Walter K; Kotzin, Jonathan J; McCright, Sam J et al. (2018) Control of Immune Cell Homeostasis and Function by lncRNAs. Trends Immunol 39:55-69
Rickels, Michael R; Peleckis, Amy J; Dalton-Bakes, Cornelia et al. (2018) Continuous Glucose Monitoring for Hypoglycemia Avoidance and Glucose Counterregulation in Long-Standing Type 1 Diabetes. J Clin Endocrinol Metab 103:105-114
Guan, Dongyin; Xiong, Ying; Borck, Patricia C et al. (2018) Diet-Induced Circadian Enhancer Remodeling Synchronizes Opposing Hepatic Lipid Metabolic Processes. Cell 174:831-842.e12

Showing the most recent 10 out of 720 publications